Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | The mechanism of action of CBM588, a live bacteria product for increasing IO efficacy

Nazli Dizman • 6 Jun 2022
ASCO 2022
General CBM588

Nazli Dizman, MD, Yale University School of Medicine, New Haven, CT, provides an overview of CBM588, a strain of nonpathogenic bacteria that is a component of the gut microbiome. Given orally, it passes through the colon and produces short-chain fatty acids. CBM588 is associated with increased efficacy of immune checkpoint inhibitors in various cancer types. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Nazli Dizman

1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
3:27
Characterization of the microbial resistome in a prospective trial of CBM588 in mRCC
Nazli Dizman • 6 Jun 2022
1:19
Modulating the gut microbiome to improve immune checkpoint inhibitor efficacy
Nazli Dizman • 6 Jun 2022

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals